Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Acer Therapeutics (ACER) Share Price
Media stories about Acer Therapeutics (NASDAQ:ACER) have trended somewhat positive recently, according to Accern. Accern rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Acer Therapeutics earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 44.9509581128263 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Acer Therapeutics (ACER) traded up $0.07 on Friday, hitting $19.10. The stock had a trading volume of 25,731 shares, compared to its average volume of 41,283. The firm has a market cap of $140.20, a PE ratio of -3.32 and a beta of 2.24. Acer Therapeutics has a 1-year low of $5.69 and a 1-year high of $22.63.
Acer Therapeutics (NASDAQ:ACER) last posted its quarterly earnings results on Monday, November 13th. The biopharmaceutical company reported ($1.09) EPS for the quarter. research analysts predict that Acer Therapeutics will post -1.48 earnings per share for the current fiscal year.
WARNING: This article was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.dailypolitical.com/2018/01/20/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-acer-therapeutics-acer-share-price.html.
About Acer Therapeutics
Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.